دورية أكاديمية
Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study.
| العنوان: | Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study. |
|---|---|
| المؤلفون: | Martins JO; Department of Dental Clinic, Faculty of Pharmacy Dentistry and Nursing Federal University of Ceará Rua Monsenhor Furtado, S/N, Rodolfo Teófilo CE, 60430-355, Fortaleza, CE, Brazil marcelaborges4321@hotmail.com., Borges MM, Malta CE, Guerra JM, Crispim AA, Coelho BC, Silva LF, Silva PG |
| المصدر: | Medicina oral, patologia oral y cirugia bucal [Med Oral Patol Oral Cir Bucal] 2024 Mar 01; Vol. 29 (2), pp. e248-e254. Date of Electronic Publication: 2024 Mar 01. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Medicina Oral S.L Country of Publication: Spain NLM ID: 101231694 Publication Model: Electronic Cited Medium: Internet ISSN: 1698-6946 (Electronic) Linking ISSN: 16984447 NLM ISO Abbreviation: Med Oral Patol Oral Cir Bucal Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Valencia, España : Medicina Oral S.L., [2004]- |
| مواضيع طبية MeSH: | Carcinoma, Squamous Cell*/pathology , Head and Neck Neoplasms*/drug therapy , Head and Neck Neoplasms*/complications , Stomatitis*/chemically induced, Humans ; Female ; Aged ; Male ; Cetuximab/adverse effects ; Retrospective Studies ; Cross-Sectional Studies ; Undertreatment ; Risk Factors |
| مستخلص: | Background: This study retrospectively analyzed the risk factors for oral mucositis (OM) during cetuximab treatment. Material and Methods: We screened patients using cetuximab and retrospectively evaluated the presence of OM based on medical records. We collected information from 2 years of evaluations. Patient medical records were reviewed to obtain data on chemotherapy cycle and dose, sex, age, primary tumor, TNM stage, and head and neck radiotherapy (HNR) history. The X2 test and multinomial logistic regression were used for statistical analysis (SPSS 20.0, p < 0.05). Results: Among 1831 patients, OM was showed in 750 in any grade (41%), during cetuximab treatment. Most patients were female (n=944, 51.6%), <70years-old (n=1149, 62.8%), had larynx cancer (n=789, 43.1%) in T4 (n=579, 47.7%), N0 (n=509, 52.6%) stages. Primary tumor surgery was performed in 1476 (80.6%) patients, radiotherapy in 606 (33.1%) patients and cetuximab protocols most used involved up to four cycles (n=1072, 58.5%) of <400mg (n=996, 54.4%) cetuximab doses. Female (OR [odds ratio] = 2.17, CI95% = 1.26-3.75), >70 years-old patients (OR = 16.02, CI95% = 11.99-21.41), with HHNR (OR = 1.84, 1.41-2.40), treated with >4 cycles (OR = 1.52, CI95% = 1.16-2.01) and high doses of cetuximab (OR = 3.80, CI95% = 2.52-5.71) are the greatest risk factors for OM. Conclusions: Since the clinical benefit of cetuximab in the treatment of older patients is limited and there is a high OM, especially in women with head and neck treated with radiotherapy, high doses and a high number of cetuximab cycles must be administered with caution. |
| References: | Exp Biol Med (Maywood). 2010 Aug;235(8):907-20. (PMID: 20562132) Nat Rev Cancer. 2012 Mar 22;12(4):237-51. (PMID: 22437869) Mol Biol Rep. 2018 Dec;45(6):2935-2940. (PMID: 30311129) J Exp Clin Cancer Res. 2020 Oct 7;39(1):210. (PMID: 33028357) J Dent Sci. 2021 Oct;16(4):1241-1246. (PMID: 34484592) BMC Cancer. 2018 Oct 5;18(1):957. (PMID: 30290786) JAAD Case Rep. 2018 Sep 14;4(8):811-813. (PMID: 30246135) Rev Saude Publica. 2010 Jun;44(3):559-65. (PMID: 20549022) Health Technol Assess. 2010 May;14 Suppl 1:1-8. (PMID: 20507797) Biol Pharm Bull. 2022;45(3):333-338. (PMID: 35228399) Phytother Res. 2016 Nov;30(11):1879-1885. (PMID: 27555604) Med Oral Patol Oral Cir Bucal. 2021 Jul 1;26(4):e494-e501. (PMID: 33772569) N Engl J Med. 2006 Feb 9;354(6):567-78. (PMID: 16467544) Curr Cancer Drug Targets. 2010 Feb;10(1):80-95. (PMID: 20088790) Strahlenther Onkol. 2012 Jan;188(1):49-55. (PMID: 22194030) Support Care Cancer. 2006 Sep;14(9):974-6. (PMID: 16502004) J Dermatolog Treat. 2014 Oct;25(5):424-7. (PMID: 23167307) Lancet. 2019 Jan 5;393(10166):40-50. (PMID: 30449625) Radiother Oncol. 2011 Jan;98(1):38-41. (PMID: 21159400) Drugs. 2020 Jun;80(8):797-811. (PMID: 32333236) N Engl J Med. 2008 Sep 11;359(11):1116-27. (PMID: 18784101) J Clin Oncol. 2007 Jun 1;25(16):2191-7. (PMID: 17538164) Medicina (Kaunas). 2019 Jan 22;55(2):. (PMID: 30678228) Expert Opin Biol Ther. 2018 Apr;18(4):483-493. (PMID: 29534625) J Cancer. 2012;3:257-61. (PMID: 22712026) Dent Clin North Am. 2014 Apr;58(2):341-9. (PMID: 24655526) Cochrane Database Syst Rev. 2016 Aug 16;(8):CD011325. (PMID: 27529826) Ther Adv Med Oncol. 2020 Dec 08;12:1758835920975355. (PMID: 33343720) J Clin Oncol. 2011 Sep 1;29(25):3419-26. (PMID: 21810686) Cancer Chemother Pharmacol. 2018 Oct;82(4):571-583. (PMID: 30006755) |
| المشرفين على المادة: | PQX0D8J21J (Cetuximab) |
| تواريخ الأحداث: | Date Created: 20231122 Date Completed: 20240304 Latest Revision: 20240320 |
| رمز التحديث: | 20240320 |
| مُعرف محوري في PubMed: | PMC10945870 |
| DOI: | 10.4317/medoral.26237 |
| PMID: | 37992137 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1698-6946 |
|---|---|
| DOI: | 10.4317/medoral.26237 |